Amputations under PMB Regulations: The Latest CMScript

By Staff Writer

January 20, 2023

Council for Medical Schemes latest CMScript focusing on amputations under PMB regulations. Amputation, the removal or loss of a body part, can drastically alter a person’s life. It impacts an individual’s mobility, work capabilities, social interactions, and independence. This article explores the causes of amputations, preventative measures, and the journey towards recovery and rehabilitation.

Life After Amputation: Recovery and Rehabilitation

Amputations due to traumatic and crush injuries, severe burns, diabetes mellitus, peripheral artery diseases, severe infections, and cancers must be funded in line with the PMB Regulations. This would include diagnosis, treatment, and care of PMBs irrespective of the member’s option.

Prosthetic limbs replace the function of the lost body part and are recommended based on the type of amputation, the patient’s general health, and the tasks expected to be performed using the prosthesis. However, not all individuals are suitable for a prosthetic limb, particularly those with serious health conditions such as heart failure.

Preventing Amputations

Preventing amputations involves addressing the underlying issues that may necessitate such a procedure. Lifestyle modifications, including a balanced diet, regular exercise, quitting smoking, and maintaining stable blood sugar, blood pressure, and cholesterol levels, are essential. Regular examination of the legs and feet for sores or changes in skin colour or temperature is also crucial.

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...

By Staff Writer

The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

By Staff Writer

August 21, 2025

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-lin...